FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery
- FDA 近 90 天出现 37 次
- 上一次：2 天前 · RFK Jr. proposes FDA look the other way on unproven peptides, report says
发生了什么
The U.S. Food and Drug Administration today granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly) that may allow some patients with locally advanced rectal cancer to avoid common treatments that can have a lasting impact on their daily life.
摘要按规则整理自下方来源原文